Royal Bank of Canada Cuts Perspective Therapeutics (NYSE:CATX) Price Target to $16.00

Perspective Therapeutics (NYSE:CATX) had its price objective decreased by Royal Bank of Canada from $25.00 to $16.00 in a research note published on Monday,Benzinga reports. Royal Bank of Canada currently has an outperform rating on the stock.

A number of other brokerages have also recently commented on CATX. Oppenheimer cut their price target on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research report on Friday, November 22nd. Wedbush restated an “outperform” rating and set a $11.00 target price (down previously from $20.00) on shares of Perspective Therapeutics in a research report on Thursday, November 21st. Truist Financial initiated coverage on Perspective Therapeutics in a report on Wednesday, September 25th. They issued a “buy” rating and a $21.00 target price for the company. UBS Group began coverage on Perspective Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $20.00 price target on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Perspective Therapeutics in a research note on Monday, September 9th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $15.14.

Perspective Therapeutics Trading Down 6.4 %

Shares of NYSE:CATX opened at $4.12 on Monday. Perspective Therapeutics has a 52 week low of $2.28 and a 52 week high of $19.05. The business’s fifty day simple moving average is $10.96.

Perspective Therapeutics (NYSE:CATX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.21). Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. The firm had revenue of $0.37 million for the quarter. Equities analysts anticipate that Perspective Therapeutics will post -0.87 earnings per share for the current year.

Insider Activity at Perspective Therapeutics

In related news, CFO Jonathan Robert Hunt acquired 12,829 shares of the stock in a transaction dated Monday, November 25th. The stock was purchased at an average cost of $3.82 per share, with a total value of $49,006.78. Following the completion of the purchase, the chief financial officer now directly owns 48,800 shares in the company, valued at $186,416. This trade represents a 35.66 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Johan M. Spoor bought 14,500 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The shares were bought at an average cost of $3.78 per share, for a total transaction of $54,810.00. Following the transaction, the chief executive officer now owns 152,072 shares of the company’s stock, valued at $574,832.16. The trade was a 10.54 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 33,595 shares of company stock valued at $126,625. 3.52% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in CATX. nVerses Capital LLC purchased a new stake in Perspective Therapeutics in the 3rd quarter valued at about $57,000. US Bancorp DE grew its holdings in shares of Perspective Therapeutics by 142.7% in the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after acquiring an additional 3,866 shares in the last quarter. Victory Capital Management Inc. bought a new position in shares of Perspective Therapeutics in the second quarter valued at approximately $117,000. Point72 DIFC Ltd purchased a new stake in shares of Perspective Therapeutics during the second quarter valued at approximately $118,000. Finally, Intech Investment Management LLC bought a new stake in Perspective Therapeutics during the third quarter worth $137,000. 54.66% of the stock is owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.